BiomX (NYSEMKT:PHGE) Trading Down 2.3% – Here’s Why

BiomX Inc. (NYSEMKT:PHGE) shares were down 2.3% during trading on Tuesday . The company traded as low as $0.93 and last traded at $0.94. Approximately 34,736 shares traded hands during trading, a decline of 49% from the average daily volume of 68,601 shares. The stock had previously closed at $0.96.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of BiomX in a research report on Friday, August 16th.

BiomX Stock Down 2.3 %

The company has a debt-to-equity ratio of 0.51, a current ratio of 2.84 and a quick ratio of 2.84. The stock has a market cap of $65.62 million, a price-to-earnings ratio of -1.54 and a beta of 1.29. The firm’s fifty day moving average price is $1.11 and its two-hundred day moving average price is $2.48.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BiomX stock. Ikarian Capital LLC acquired a new stake in shares of BiomX Inc. (NYSEMKT:PHGE) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 10,817,327 shares of the company’s stock, valued at approximately $4,868,000. Ikarian Capital LLC owned approximately 19.59% of BiomX as of its most recent filing with the SEC. 40.57% of the stock is currently owned by hedge funds and other institutional investors.

About BiomX

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.